Name: FENNEC PHARMACEUTICALS INC (FENC) Stock
Brand: FENNEC PHARMACEUTICALS INC
Rating: 4 (3 reviews)

FENC Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

10 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

17 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

18 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada

19 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

4 months ago - By: The Motley Fool

Fennec Q2 Sales Jump 33 Percent

4 months ago - By: Benzinga

Fennec Pharmaceuticals Earnings Preview

7 months ago - By: Zacks Investment Research - Mentions: JYNT EHC WGS

The Joint Misses Q1 Earnings Estimates on Rising Expenses

22 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

22 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

23 days ago - By: Zacks Investment Research - Mentions: VREX

Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates

23 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

23 days ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

24 days ago - By: Zacks Investment Research - Mentions: BOLT

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: NAGE

Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: URGN

Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

4 months ago - By: The Motley Fool

Fennec (FENC) Q2 2025 Earnings Call Transcript

4 months ago - By: Zacks Investment Research - Mentions: OCS

Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

4 months ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

4 months ago - By: Zacks Investment Research - Mentions: CDXS

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: CUE

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: ROIV

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

4 months ago - By: Zacks Investment Research - Mentions: CON

Concentra Group (CON) Matches Q2 Earnings Estimates

6 months ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Announces Results of Annual Meeting

7 months ago - By: Zacks Investment Research - Mentions: ACHC EHC WGS

Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions

7 months ago - By: Zacks Investment Research - Mentions: BHST

Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Fennec Pharmaceuticals Inc. - Mentions: FRX.CA

Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Zacks Investment Research - Mentions: CUE

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: ACAD

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

7 months ago - By: Zacks Investment Research - Mentions: ABCL

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates